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Abstract
Objectives Hormone receptors play an important role in many types of cancers. Alongside factors associated with human 
papillomavirus (HPV) infection, hormonal receptors may impact the tumorigenesis of oropharyngeal cancer.
Materials and methods This study consists of 199 consecutive oropharyngeal squamous cell carcinoma (OPSCC) patients 
diagnosed and treated with a curative intent. We examined androgen (AR), estrogen (ER; both alpha and beta), and proges-
terone receptor (PR) expressions using immunohistochemistry comparing tumor and patient characteristics.
Results AR was expressed in 16%, PR in 27% and ER-beta in 63% of the tumors. HPV- and p16-positive tumors expressed 
more AR and less PR than their negative counterparts. High PR expression was associated with poor disease-specific and 
locoregional recurrence-free survival.
Conclusion AR, PR, and ER-beta are expressed in OPSCC, and AR and PR expressions are associated with HPV and p16 
status. Furthermore, PR appears to have prognostic significance. This may allow us to investigate the role of anti-hormone 
receptors in the treatment of OPSCC.
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Introduction
The landmark study by Ang et al. 2010 firmly established 
the prognostic implication of human papillomavirus (HPV) 
in oropharyngeal squamous cell carcinoma (OPSCC) [1]. 
HPV-related tumors differ from alcohol- and tobacco-
related cancers. Patients with an HPV-related tumor are 
typically younger, often have a limited history of smoking, 
and smaller primary tumors, but present with cervical lym-
phadenopathy, and a generally good prognosis [1–3]. In the 
latest WHO classification of head and neck tumors from 
2017, the HPV-positive and -negative tumors are classified 
as distinct entities [4]. HPV positivity is detected in over 
60% of OPSCC in USA [5], and in more than 80% of cases 
in some European countries [6, 7]. Men are more frequently 
affected [1, 5].
While the treatment response of HPV-related OPSCCs 
is generally good [1], individual variation exists. Identify-
ing factors associated with tumor behavior could enable a 
more individualized treatment approach. Hormone recep-
tors play a significant role in many types of cancers, and 
are thus involved in targeted treatments [8]. For example, 
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anti-hormone therapies, such as tamoxifen and fulvestrant, 
are widely used in breast and prostate cancers [9, 10]. How-
ever, in OPSCC, the expression and role of hormone recep-
tors, as well as their association with HPV status remain 
poorly understood.
Androgen receptors (AR) are primarily male sex-related 
hormonal receptors. They are expressed by oral mucosal 
cells [11], and normal prostate and mammary glands [12]. 
In malignancies, AR expression typically associates with 
favorable prognoses [13, 14], although not always [15, 16]. 
Only a few studies have addressed AR expression in head 
and neck squamous cell carcinoma (HNSCC) [13, 17–20], 
and very little is known about their expression in OPSCC 
[13].
Estrogen receptors (ER; types alpha and beta) and proges-
terone receptors (PR) are nuclear receptors that act as DNA-
binding transcription factors. Normal salivary glands and 
oral mucosal cells in particular express ER-beta [18]. Colella 
et al. [19] showed an increase of ER-alpha transcription in 
OSCCs, suggesting the involvement of estrogen hormone in 
oral cancer. Normal oral mucosa [20], as well as laryngeal 
and oral SSCs [20–22] express PR, which appears to be a 
favorable prognostic factor [23].
In this study, we examined the expression of AR, ER, 
and PR in a series of 201 consecutive OPSCC patients. We 
compared expression levels with clinical parameters and 
outcomes. Specially, we explored the relationship between 
sex hormone receptors and HPV status and the expression 
of the p16 protein, which have not been previously studied.
Materials and methods
Patient selection
We reviewed data for a total of 331 consecutive patients 
diagnosed with oropharyngeal cancer at the Department 
of Otorhinolaryngology—Head and Neck Surgery, Hel-
sinki University Hospital between 1 January 2000 and 31 
December 2009. We excluded from the analysis the follow-
ing patients: patients receiving palliative treatment (n = 44), 
concurrent (n = 5) or previously treated HNSCC (n = 11), 
histology other than SCC or subtype of SCC (n = 18), tumor 
tissue unavailability (n = 52), or patients without pretreat-
ment samples (n = 2). In total, our final study cohort con-
sisted of 199 patients treated with a curative intent and for 
whom tumor tissue was available for HPV, p16, and hor-
mone receptor analysis.
Data source from hospital records
We collected clinicopathological data on patient’s age, sex, 
tumor histology, grade, TNM classification [24], stage, 
primary treatment, tumor recurrence and status at last fol-
low-up. The median follow-up time for patients was 5.0 
years, and all patients had a minimum follow-up of 3 years 
or until death. The dates and causes of death were obtained 
from Statistics Finland. The Research Ethics Board of the 
Hospital District of Helsinki and Uusimaa approved the 
study design and granted permission to conduct this study. 
Patient data are described in further detail in our previous 
study [25].
From our 199 patients, 130 (65%) underwent primary 
surgery and 116 (89%) received postoperative radiother-
apy (RT) or chemoradiotherapy (CRT). In total, 14 (11%) 
patients remained who did not receive postoperative RT 
or CRT: five due to stage I or II disease and nine due 
to patient-related factors. A total of 69 (35%) patients 
received definitive oncological treatment (RT or CRT), 
9 of whom underwent complementary surgery during the 
primary treatment phase.
Immunohistochemical staining
Preparation of tissue microarray (TMA) blocks and immu-
nohistochemical staining was completed as described pre-
viously [26]. TMA blocks were cut into 4 µm thick sec-
tions, deparaffinized in xylene, and rehydrated through a 
graded alcohol series. Antigen retrieval was achieved by 
heating the samples in a 98 °C Tris–HCl buffer (pH8.5) for 
20 min in a pretreatment PT module (Lab Vision Corp., 
Fremont, CA, USA). Samples were cooled to room temper-
ature and incubated in methanol containing 1.6% hydrogen 
peroxidase for 30 min and then treated with horse serum 
to block the non-specific binding sites. The immunostain-
ing was performed in Autostainer 480 (LabVision) with 
the following antibodies: monoclonal antibody (mAb) ER-
alpha diluted to 1:100 (Leica Biosystem Newcastle Ltd), 
mAb ER-beta diluted to 1:100 (Leica Biosystem Newcastle 
Ltd), and mAb PR diluted to 1:100 (Leica Biosystem New-
castle Ltd). Stainings were visualized using the Dako Real 
Detection System. MAb PR reacts with both progesterone 
receptors A and B (PR-A and PR-B). We used Discovery 
Automated IHC stainer with the ultraView Universal Alka-
line Phosphatase Red Detection Kit (catalog no. 760–501, 
Ventana Medical Systems, Tuscon, Arizona, USA) in the 
staining of mAb AR diluted to 1:50 (Dako, Agilent Tech-
nologies, Santa Clara, California, US). Breast cancer tis-
sue served as the positive control for each antibody. In 
each staining, a slide without a primary antibody served 
as the negative control.
p16 immunohistochemical staining for this series was 
performed in our previous study [25], in which we used 
monoclonal mouse anti-human p16INK4a (9517 CINtec 
Histology Kit, MTM laboratories).
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HPV in situ hybridization
HPV in situ hybridization was performed in our previous 
study [25]. We performed the Ventana Inform HPV in situ 
hybridization (ISH) assay using a high-risk HPV probe 
(16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 66) and 
iVIEW Blue detection kit in Benchmark XT series stainer 
(Tuscon, Arizona, USA). To perform the assay, we used 
5-µm thick sections and extended Ventana cell-condition-
ing solution (CC2) pretreatment with an incubation time 
of 32 min with ISH protease 3. We considered HPV status 
as positive if any spot was positive using ISH.
Immunoscoring
Two researchers (JH and HM) individually evaluated the 
TMA slides in a blinded manner without knowledge of 
the clinicopathological data. In the case of a discrepancy, 
a consensus score was used for further analysis. AR and 
ER-beta expressions were nuclear and scored accord-
ing to the percentage as negative = (0), < 10% = mild 
(1), 10–50% = moderate (2), and > 50% = strong (3). 
PR expression was cytoplasmic and scored according 
to the intensity as negative (0), mild (1), moderate (2), 
and strong (3). From tumor spots, we assigned the high-
est immunoscore for further analysis. Since all tumor 
samples remained negative for ER-alpha, no scoring was 
performed.
We used whole tissue slides to examine the staining 
patterns across the entire tumor sample. In total, ten whole 
tumor slides were stained for AR and PR and eight for ER-
beta. The staining of whole slides for AR, PR and ER-beta 
showed similarity to the staining seen in TMA slides.
Statistical analysis
We used SPSS version 20 (SPSS, Inc. Chicago, IL, USA) 
for all statistical analyses. We calculated the statistical 
significance of differences between categorical variables 
using the Pearson’s Chi square test, selecting asympto-
matic or exact p values when suitable. Our prognostic 
model was the Kaplan–Meier (KM) estimate with the log-
rank test, wherein we used death from disease (disease-
specific survival, DSS) or locoregional or distant recur-
rence (recurrence-free survival, RFS) as the endpoint. The 
Cox proportional hazards model served in the multivariate 
analysis of prognostic factors. The proportional hazards 
assumption was tested using KM curves. Factors with a 
univariate p value of < 0.1 were selected for multivariate 
analysis. A two-sided p value of < 0.05 was considered 
statistically significant.
Results
Expression of AR
AR expression was detected in 16% (31/199) of the tumors, 
of which 39% (12/31) showed mild, and 61% (19/31) strong 
expression (Table 1). None of the samples showed moder-
ate staining. In the whole tissue samples, AR expression 
appeared predominantly along the invasive front (Fig. 1).
AR expression appeared more often in HPV- and 
p16-positive tumors than in HPV- and p16-negative tumors. 
Among men, 17% (25/147) of samples were AR positive, 
which fell to 12% (6/52) in women. In addition, AR expres-
sion was stronger among non-smokers or ex-smokers. We 
found no association between AR expression and the use of 
alcohol, tumor site, grade, TNM class, stage, DSS, or RFS 
(Table 1; Fig. 2).
Expression of ER
ER-beta expression was present in 63% (126/199) of sam-
ples, which was mild in 36% (45/126), moderate in 29% 
(36/126) and strong in 36% (45/126) of immunopositive 
tumors (Table 2). In whole tissue samples, ER-beta expres-
sion appeared both along the central and invasive regions, 
in addition to the basal layer of normal epithelium (Fig. 1).
We found no statistical association between ER-beta and 
p16 or HPV status, nor with any of the patient or tumor 
characteristics, DSS, or RFS. All tumors remained negative 
for ER-alpha (Table 2; Fig. 2).
Expression of PR
PR was expressed in 27% (54/199) of tumors, with mild in 
35% (19/54), moderate in 46% (25/54), and strong in 19% 
(10/54) of the immunopositive tumors (Table 3). In whole 
tissue samples, PR expression was predominantly seen along 
the central part of the tumor, but not along the invasive front 
or invasive islands (Fig. 1).
PR expression appeared more commonly in HPV- and 
p16-negative tumors than in HPV- and p16-positive tumors 
(Table  3; Fig.  3). Smokers or ex-smokers exhibited a 
stronger PR tumor expression than non-smokers, often with 
a history of heavy alcohol use (Table 3). In addition, PR 
expression associated with the tumor grade. High-grade 
tumors (often linked to HPV) showed significantly lower 
PR expression than tumors of lower grades (p < 0.001). We 
found no association between PR expression and sex, TNM 
class, or stage. In addition, patients with a strong PR tumor 
expression had worse 5-year DSS than those with negative 
staining (p = 0.001) (Fig. 2). Similarly, patients exhibiting 
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a strong PR expression had lower 5-year locoregional RFS 
rate than those with negative staining (p = 0.041) (Fig. 2), 
although PR expression did not associate with distant RFS.
In the multivariate analysis, high PR expression conferred 
a  3.8-fold risk of death of disease (Table 4). Other inde-
pendent factors for poor prognosis included HPV negativity, 
T4 class, N2–3 classes, and male gender.
Discussion
In this study, we demonstrate the expression of AR, ER, and 
PR in tumor samples in a series of 199 OPSCC patients. 
We found that a strong PR expression was associated with 
shorter DSS and RFS. In addition, we found that both HPV 
and p16 positivity associated with the upregulation of AR 
and the downregulation of PR expression, although they did 
not associate with ER expression. In cervical cancer, Bek-
kers et al. [27] have suggested that ER downregulation may 
represent the first alteration occurring in normal epithelium 
during carcinogenesis. To date, we have found no previous 
studies connecting AR and HPV, a relationship requiring 
further investigations.
Both OPSCC and laryngeal carcinoma occur more fre-
quently in men [5, 28]. This could be partly explained by 
men being more often exposed to high-risk behaviors such as 
tobacco, alcohol use, and oral sex [29]. In accordance with 
this, 74% of our samples were from male patients. Our study 
revealed no statistical association between hormone recep-
tor expressions and sex, although the AR high immunoex-
pression occurred primarily among men. In tongue SCC, 
Marocchio et al. [30] found that men presented with AR 
positivity more often, whereas ER expression did not dif-
fer between men and women. A study by Goulioumis et al. 
[31] showed that more than 50% of laryngeal carcinomas 
are AR immunopositive. By contrast, Bianchini et al. [21] 
found no AR positivity in laryngeal carcinoma, although 
ER expression appeared in 53% and PR expression in 73% 
of the tumors, and these expressions were associated with 
an absence of lymph node metastasis. In the present study, 
we were not able to show any relation between PR expres-
sion and occurrence of lymph node metastasis. However, our 
results revealed an association between PR positivity and 
HPV negativity in the samples and it is known that the pat-
tern of metastatic disease is different between HPV-negative 
and -positive OPSCC. This phenomenon remains to be fur-
ther investigated.
In our series, 16% of the tumors were AR positive, with 
the strongest expression occurring along the invasive front. 
AR appears to be related to the development of cancers by 
increasing cell migration and invasion [32]. In oral cavity 
SCC, findings appear contradictory: for instance, Nehse and 
Tunn [20] revealed that the expression of AR was lower in 
Table 1  Expression of androgen receptors and its association with 
clinicopathological factors in OPSCC
p  values indicated in bold are significant
*Chi square test with asymptotic p value
**Chi square test with exact p value
Variables Androgen receptor scoring p value
Negative Weak Strong Total number
Sex
 Men 122 8 17 147
 Women 46 4 2 52
 Total 168 12 19 199 0.196**
Smoking
 Never 19 2 5 26
 Ex-smoker 39 2 6 47
 Regularly 88 5 2 95
 Total 146 9 13 168 0.002**
Alcohol abuse
 No 51 2 8 61
 Previously 22 1 0 23
 Yes 32 3 2 37
 Total 105 6 10 121 0.329**
HPV
 Positive 74 11 18 103
 Negative 94 1 1 96
 Total 168 12 19 199 < 0.001*
p16
 Positive 86 10 19 115
 Negative 82 2 0 84
 Total 168 12 19 199 < 0.001**
Grade
 Gr1 16 2 0 18
 Gr2 66 3 6 75
 Gr3 86 7 13 106
 Total 168 12 19 199 0.135**
Tumor site
 Anterior wall 53 2 4 59
 Lateral wall 91 10 15 116
 Posterior wall 3 0 0 3
 Superior wall 21 0 0 21
 Total 168 12 19 199 0.426**
T class
 T1 33 1 4 38
 T2 60 7 7 74
 T3 38 1 6 45
 T4 37 3 2 42
 Total 168 12 19 199 0.616**
N class
 N0 37 1 1 39
 N+ 131 11 18 160
 Total 168 12 19 199 0.057**
Stage
 I–II 29 0 1 30
 III–IV 139 12 18 169
 Total 168 12 19 199 0.077**
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SCC than in the normal oral mucosa. Yet, Wu et al. [17] 
reported opposing results, finding that 67% of OSCC speci-
mens were AR positive. These contradictory reports may 
result from the different methods used in these two studies.
ER carries several physiological functions, having a role 
in the growth and behavior of cancers, particularly in breast 
cancer [33]. Lopez-Romero et al. [34] showed that cervical 
malignant cells lose their ER-alpha expression, but maintain 
the ER-beta expression. In addition, it has been shown that 
HPV-infected cervical dysplasia exhibits ER downregula-
tion [27]. Furthermore, a study on lingual SCC revealed 
that tumors only expressed ER-beta [35]. These studies are 
consistent with our findings showing that OPSCC expresses 
ER-beta but not ER-alpha. However, Gingelmaier et al. [36] 
reported that neither ER-alpha nor ER-beta were expressed 
in HPV-positive adenosquamous endometrial carcinoma.
In our cohort, 27% of the tumors expressed PR. A 
study by Grimm et al. [37] found no expression of PR 
Fig. 1  Immunohistochemical staining pattern of AR, PR, and ER-
beta receptors in oropharyngeal carcinoma. a OPSCC with positive 
nuclear AR expression (magnification ×40), in which the expression 
appears along the invasive front. b OPSCC with positive nuclear AR 
expression (magnification ×400). c OPSCC with negative AR expres-
sion (magnification ×400). d OPSCC with positive cytoplasmic PR 
expression (magnification ×40), in which the expression appears 
along the central part of the tumor rather than the invasive front. e 
OPSCC with positive cytoplasmic PR expression (magnification 
×400). f OPSCC with negative PR expression (magnification ×400). 
g OPSCC with positive nuclear ER-beta expression (magnification 
×40), in which the expression appears both along the central and 
invasive parts, and in addition along the basal layer of normal epithe-
lium. h OPSCC with positive nuclear ER expression (magnification 
×400). i OPSCC with negative ER expression (magnification ×400)
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in OSCC. Another study by Nehse and Tunn [20] found 
PR present in only 40% of OSCC, and in all normal oral 
mucosa samples. In our series, PR expression was cyto-
plasmic, although staining for PR is typically nuclear, such 
as in our control slides. This cytoplasmic positivity may 
result from the different isoforms of PR. Some of these 
isoforms carry a defective DNA-binding domain lacking 
the nuclear localization signal [38]. A similar unusual 
cytoplasmic expression pattern was detected with an ER-
beta isomer in ovarian cancer [39]. This suggests that the 
pathogenesis of some types of cancer may cause a defect 
in DNA-binding site for hormone receptors. In our study, 
PR expression appeared in HPV- and p16-negative tumors, 
behaving more aggressively, and significantly correlating 
with worse outcomes.
In many malignancies, hormone receptors correlate with 
aggressiveness and the metastatic potential of the tumors 
[35, 40, 41]. In terms of survival, findings remain inconsist-
ent. In our cohort, only PR expression is associated with 
survival. A positive prognostic role for high AR expression 
has been shown for various malignant tumors, i.e., blad-
der [42], breast [14], and prostate cancer [43]. A study on 
HNSCC by Rades et al. [13] showed that the expression of 
AR is an independent prognostic factor for better survival in 
advanced stage diseases. Conversely, in some other cancers, 
such as prostate [41], esophageal [32], and thyroid cancer 
[44], AR expression correlates with more aggressive tumors. 
In addition, a poor prognosis accompanies salivary duct car-
cinoma with 70 to 98% of tumors showing AR immunoposi-
tivity [15, 16]. We found no correlation between AR or ER 
Fig. 2  Using the Kaplan–Meier, a disease-specific survival (DSS) 
curve for 199 patients in relation to AR expression, b disease-specific 
survival (DSS) curve for 199 patients in relation to ER-beta expres-
sion, c disease-specific survival (DSS) curve for 199 patients in rela-
tion to PR expression, d locoregional recurrence-free survival curve 
for 199 patients in relation to PR expression
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Table 2  Expression of 
estrogen-beta receptors 
and its association with 
clinicopathological factors in 
OPSCC
*Chi square test with asymptotic p value
**Chi square test with exact p value
Variables Estrogen-beta receptor scoring p value
Negative Weak Moderate Strong Total number
Sex
 Men 55 31 27 34 147
 Women 18 14 9 11 52
 Total 73 45 36 45 199 0.907*
Smoking
 Never 5 10 5 6 26
 Ex-smoker 20 9 6 12 47
 Regularly 30 19 22 24 95
 Total 55 38 33 42 168 0.824*
Alcohol abuse
 No 20 16 13 12 61
 Previously 8 4 2 9 23
 Yes 10 9 10 8 37
 Total 38 29 25 29 121 0.480*
HPV
 Positive 38 30 17 18 103
 Negative 35 15 19 27 96
 Total 73 45 36 45 199 0.134*
p16
 Positive 41 32 20 22 115
 Negative 32 13 16 23 84
 Total 73 45 36 45 199 0.353*
Grade
 Gr1 8 2 3 5 18
 Gr2 25 21 12 17 75
 Gr3 40 22 21 23 106
 Total 73 45 36 45 199 0.927**
Tumor site
 Anterior wall 19 13 12 15 59
 Lateral wall 47 27 18 24 116
 Posterior wall 1 0 1 1 3
 Superior wall 6 5 5 5 21
 Total 73 45 36 45 199 0.972**
T class
 T1 15 8 8 7 38
 T2 27 19 12 16 74
 T3 13 13 9 10 45
 T4 18 5 7 12 42
 Total 73 45 36 45 199 0.528*
N class
 N0 16 6 4 13 39
 N+ 57 39 32 32 160
 Total 73 45 36 45 199 0.584*
Stage
 I–II 10 5 3 12 30
 III–IV 63 40 33 33 169
 Total 73 45 36 45 199 0.130*
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Table 3  Expression of 
progesterone receptors 
and its association with 
clinicopathological factors in 
OPSCC
p  values indicated in bold are significant
*Chi square test with asymptotic p value
**Chi square test with exact p value
Variables Progesterone receptor scoring p value
Negative Weak Moderate Strong Total number
Sex
 Men 113 12 14 8 147
 Women 32 7 11 2 52
 Total 145 19 25 10 199 0.106**
Smoking
 Never 24 2 0 0 26
 Ex-smoker 42 1 3 1 47
 Regularly 55 16 16 8 95
 Total 121 19 19 9 168 < 0.001**
Alcohol abuse
 No 51 4 5 1 61
 Previously 15 3 2 3 23
 Yes 21 5 6 5 37
 Total 87 12 13 9 121 0.003**
HPV
 Positive 91 5 7 0 103
 Negative 54 14 18 10 96
 Total 145 19 25 10 199 < 0.001**
p16
 Positive 102 5 7 1 115
 Negative 43 14 18 9 84
 Total 145 19 25 10 199 < 0.001*
Grade
 Gr1 6 5 4 3 18
 Gr2 45 9 14 7 75
 Gr3 94 5 7 0 106
 Total 145 19 25 10 199 < 0.001**
Tumor site
 Anterior wall 43 6 9 1 59
 Lateral wall 92 7 12 5 116
 Posterior wall 1 0 1 1 3
 Superior wall 9 6 3 3 21
 Total 145 19 25 10 199 0.014**
T class
 T1 33 3 1 1 38
 T2 51 8 10 5 76
 T3 33 3 6 3 45
 T4 28 5 8 1 42
 Total 145 19 25 10 199 0.155**
N class
 N0 24 6 6 3 39
 N+ 121 13 19 7 160
 Total 145 19 25 10 199 0.136**
Stage
 I–II 18 5 4 3 30
 III–IV 127 14 21 7 169
 Total 145 19 25 10 199 0.122**
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expression and survival. Yet, a study by Lukits et al. [45] 
combining laryngeal and hypopharyngeal SCCs showed that 
ER positivity associates with poor survival.
Currently, anti-hormone therapy stands as one of the pri-
mary treatment options for various types of cancers. Stromal 
PR may play a suppressive role in prostate cancer enabling 
its use as a therapeutic target [46]. In vitro studies suggest 
that anti-hormone agents, such as tamoxifen, could have a 
therapeutic role in OSCC [35] and HNSCC in general [47]. 
However, this hypothesis thus so far has not been supported 
by in vivo studies, showing either a complete lack [48], 
or low expression [49] of hormone receptors in laryngeal 
cancer.
In the present study, AR positivity was found more 
often among non-smokers, while PR positivity was more 
frequent among smokers and ex-smokers. Strikingly, a 
high proportion of our patients were current or former 
smokers: 98% of patients with a non-HPV-related tumor 
and 72% of patients with an HPV-related tumor (data not 
shown). The impact of smoking history on the etiology 
and treatment response of HPV-positive OPSCC remains 
unclear, although smoking significantly increases the like-
lihood of death [1].
The retrospective nature of our study results in certain 
limitations. Our data were limited particularly in relation 
to smoking and alcohol misuse. Furthermore, the num-
ber of patients from certain subgroups, such as that with 
a strong AR positivity remained limited and potentially 
impacting our findings on tumor pathogenesis, which 
was not revealed in our study. However, our material was 
homogeneous consisting of OPSCCs with solid follow-up 
data. Furthermore, we could include information on both 
HPV and p16 status. Yet, pretreatment samples remained 
unavailable for two patients, and the treatment effect on 
hormone receptor expression in these two patients could 
not be eliminated. However, excluding these patients did 
not affect our results.
Fig. 3  Using the Kaplan-Meier, a and b disease specific survival (DSS) curves for 199 patients in relation to AR in HPV subgroups, c and d dis-
ease specific survival (DSS) curves for 199 patients in relation to PR in HPV subgroups
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Conclusion
To our knowledge, this is the first study to assess hor-
mone receptors specifically in HPV-related and non-HPV-
related OPSCC. We found that AR expression appeared 
along the invasive front of the tumor more commonly 
in HPV-related tumors. In contrast, PR expression more 
often accompanied HPV-negative tumors, being cytoplas-
mic along the central part of the tumor. In addition, PR 
expression is associated with poor DSS. This indicates 
that further studies in future are necessary to explore their 
role in OPSCC, as well as the possible benefit of targeted 
therapies for such patients.
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Table 4  Univariate and 
multivariate Cox regression 
analysis for disease-specific 
survival
HR hazard ratio, CI confidence interval
p  values indicated in bold are significant
Variables Univariate analysis Multivariate analysis
HR CI 95% p value HR CI 95% p value
Sex
 Male vs. female 2.2 1.0–4.9 0.054 2.4 1.1–5.7 0.035
Smoking 0.038
 Earlier vs. never 1.7 0.5–6.0 0.439
 Currently vs. never 3.3 1.0–10.7 0.048
T class 0.060 0.056
 T2 vs. T1 3.0 0.7–5.3 0.178 2.2 0.8–6.3 0.123
 T3 vs. T1 1.8 0.6–5.3 0.284 1.6 0.6–4.9 0.374
 T4 vs. T1 3.6 1.3–10.0 0.013 3.7 1.3–10.2 0.013
N class
 N2–3 vs. N0–1 2.1 1.0–4.2 0.037 2.7 1.3–5.7 0.009
AR 0.352
 1 vs. 0 1.4 0.5–3.6 0.557
 2 vs. 0 0.4 0.1–1.6 0.201
PR 0.002 0.026
 1 vs. 0 2.5 1.1–5.7 0.034 2.3 1.0–5.5 0.064
 2 vs. 0 2.7 1.3–5.8 0.011 2.2 1.0–5.1 0.054
 3 vs. 0 4.3 1.8–10.5 0.001 3.8 1.4–10.2 0.008
ER 0.927
 1 vs. 0 1.2 0.6–2.7 0.595
 2 vs. 0 1.2 0.5–2.7 0.653
 3 vs. 0 1.3 0.6–2.7 0.569
HPV
 HPV− vs. HPV+ 2.2 1.2–4.0 0.007 2.0 1.0–4.0 0.040
Treatment
 (C)RT ± Sx vs. Sx ± (C)RT 1.0 0.6–1.8 0.975
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